DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR TANZEUM
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for TANZEUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02787551 | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Recruiting | Sanofi | Phase 3 | 2016-07-01 | Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination (FRC) to GLP-1 receptor agonist (GLP-1 RA) on top of metformin (with or without pioglitazone) in patients with type 2 diabetes. To evaluate safety, efficacy and other endpoints of FRC up to the end of the extension period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TANZEUM
Condition Name
Clinical Trial Locations for TANZEUM
Trials by Country
Clinical Trial Progress for TANZEUM
Clinical Trial Phase
Clinical Trial Sponsors for TANZEUM
Sponsor Name
